Microba and Sonic Healthcare have now signed a commercial agreement to deliver Microba’s advanced infectious disease testing technology MetaPanel™ into Australia
This new metagenomic diagnostic test has been designed to identify a comprehensive panel of pathogenic microorganisms and genes to advance the standard of care in gastrointestinal infectious disease pathology
This is the first executed agreement between Microba and Sonic Healthcare (ASX: SHL) since Sonic Healthcare acquired a 19.99% equity holding in Microba and marks the first stage of the parties delivering Microba’s world leading microbiome testing technology into Sonic Healthcare’s major markets.
A video presentation of this announcement by Microba CEO Dr Luke Reid can be viewed here https://ir.microba.com/presentations/